Potassium%25252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an essential electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia in patients at risk. ## Adult Dosing * **Oral:** * **Treatment of hypokalemia:** Typically 20-60 mEq per day divided into 2-4 doses. Higher doses may be required in severe deficiency, up to 100 mEq/day, but require careful monitoring. * **Prevention of hypokalemia:** Typically 10-40 mEq per day once daily or divided. * **Intravenous (IV):** * **Treatment of hypokalemia:** Dosing depends on serum potassium levels and clinical status. Mild to moderate hypokalemia (serum K 2.5-3.5 mEq/L) may be treated with 20-40 mEq IV. Severe hypokalemia (<2.5 mEq/L) or symptomatic hypokalemia may require higher doses. * **Maximum infusion rate:** Generally not to exceed 10 mEq/hour to avoid cardiac arrhythmias. In life-threatening situations, rates up to 20-40 mEq/hour may be used with continuous cardiac monitoring, but this is typically reserved for intensive care settings. * **Maximum concentration:** Typically not to exceed 40 mEq/L in peripheral lines, and 80 mEq/L in central lines, to prevent phlebitis and pain. ## Pediatric Dosing * **Oral:** * **Treatment of hypokalemia:** 1-2 mEq/kg/day divided into 2-4 doses. Maximum dose generally 100 mEq/day. * **Prevention of hypokalemia:** 0.5-1 mEq/kg/day divided into 1-2 doses. Maximum dose generally 40 mEq/day. * **Intravenous (IV):** * Dosing is highly individualized based on serum potassium, age, and clinical condition. Common initial doses for moderate hypokalemia are 0.5-1 mEq/kg infused over 1-2 hours. * **Maximum infusion rate:** Generally 0.5-1 mEq/kg/hour, not to exceed 10-20 mEq/hour without intensive cardiac monitoring. * **Maximum concentration:** Typically 40 mEq/L in peripheral lines. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium elimination is significantly reduced in patients with renal insufficiency. Dosing should be significantly reduced and carefully monitored. * **Adrenal Insufficiency:** Patients may have increased sensitivity to potassium. ## Contraindications * Hyperkalemia. * Conditions which may predispose to hyperkalemia, such as severe renal impairment, untreated Addison's disease, severe tissue trauma, or burns. * Certain diuretic therapies (e.g., concurrent use of potassium-sparing diuretics unless specific indication and close monitoring). ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain, upper gastrointestinal irritation or ulceration. * **Cardiovascular:** Arrhythmias, cardiac arrest (especially with rapid IV infusion or hyperkalemia). * **Other:** Hyperkalemia (most serious), phlebitis (IV), local irritation. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** May increase serum potassium levels. * **NSAIDs:** May impair potassium excretion and increase the risk of hyperkalemia. * **Heparin:** May impair potassium excretion and increase the risk of hyperkalemia. ## Monitoring * **Serum potassium levels:** Frequent monitoring is crucial, especially during IV administration, dose titration, and in patients with renal impairment. * **ECG:** Essential for patients receiving IV potassium, particularly at higher doses or infusion rates, to detect cardiac abnormalities associated with hyperkalemia. * **Renal function:** Monitor BUN and creatinine. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium chloride is often poorly tolerated due to gastrointestinal side effects. Different formulations (e.g., liquid, wax matrix tablets) may improve tolerability. * Rapid IV infusion of potassium chloride can be dangerous and potentially fatal. Always dilute and infuse at recommended rates. * Monitor patients closely for signs of hyperkalemia (muscle weakness, paresthesias, ECG changes, cardiac arrest). * Ensure adequate fluid intake to minimize GI irritation with oral formulations. *** *Please verify the current prescribing information with the manufacturer's official product monograph or a reliable drug information database before making any clinical decisions.*